We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock

Delisted

ONCT was delisted on the 2nd of December, 2024.

38 hedge funds and large institutions have $2.67M invested in Oncternal Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less call options, than puts

Call options by funds: $47K | Put options by funds: $54K

24% less funds holding

Funds holding: 5038 (-12)

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

57% less capital invested

Capital invested by funds: $6.23M → $2.67M (-$3.56M)

86% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 14

Holders
38
Holders Change
-12
Holders Change %
-24%
% of All Funds
1.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
8
Reduced
13
Closed
14
Calls
$47K
Puts
$54K
Net Calls
-$7K
Net Calls Change
-$13K
Name Holding Trade Value Shares
Change
Change in
Stake
BIT
1
BlackRock Institutional Trust
California
$1.11M +$75.2K +51 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$565K +$59K +40 +8%
OIM
3
Oracle Investment Management
Connecticut
$196K
Geode Capital Management
4
Geode Capital Management
Massachusetts
$92K +$14.7K +10 +13%
BA
5
BlackRock Advisors
Delaware
$84K
Goldman Sachs
6
Goldman Sachs
New York
$65K -$23.6K -16 -20%
BFA
7
BlackRock Fund Advisors
California
$56K -$5.9K -4 -7%
Northern Trust
8
Northern Trust
Illinois
$55K -$221K -150 -74%
AQR Capital Management
9
AQR Capital Management
Connecticut
$47K -$108K -73 -62%
BCM
10
Bridgeway Capital Management
Texas
$46K
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$45K -$20.6K -14 -24%
VKH
12
Virtu KCG Holdings
New York
$32K +$20.6K +14 +78%
Millennium Management
13
Millennium Management
New York
$29K +$10.3K +7 +33%
Tudor Investment Corp
14
Tudor Investment Corp
Connecticut
$27K -$8.85K -6 -19%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$26K
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$23K -$17.7K -12 -35%
State Street
17
State Street
Massachusetts
$19K -$4.42K -3 -14%
Group One Trading
18
Group One Trading
Illinois
$19K +$2.95K +2 +12%
Citadel Advisors
19
Citadel Advisors
Florida
$19K +$5.9K +4 +27%
RIM
20
Reliant Investment Management
Tennessee
$16K +$22.1K +15 New
Charles Schwab
21
Charles Schwab
California
$12K
Bank of America
22
Bank of America
North Carolina
$10K -$156K -106 -91%
LPL Financial
23
LPL Financial
California
$9K
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$8K -$7.37K -5 -38%
Morgan Stanley
25
Morgan Stanley
New York
$7K -$48.7K -33 -85%

ONCT Hedge Fund Activity: Q3 2014 in Review

38 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2014, worth a combined $2.67M — down 57% from $6.23M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ONCT and 2 opened new positions — a net loss of 12 holders — while 13 trimmed existing stakes and 8 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $75.2K. The largest seller was Northern Trust, cutting an estimated $221K.

  • 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2014, down from 50 in Q2 2014.
  • Funds reported $2.67M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2014, down 57% quarter-over-quarter.
  • 2 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2014 and 14 closed out, a net change of -12 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2014 was BlackRock Institutional Trust, an estimated $75.2K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2014 was Northern Trust, an estimated $221K sold.

Based on aggregated 13F filings for Q3 2014.